z-logo
open-access-imgOpen Access
Natural synthesis: Biologics, biosimilars and biobetters in protein hormone therapy
Author(s) -
Sarbendra Pradhananga,
Jon R. Sayers
Publication year - 2012
Publication title -
the biochemist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 7
eISSN - 1740-1194
pISSN - 0954-982X
DOI - 10.1042/bio03401010
Subject(s) - biosimilar , hormone , biological drugs , antibody , human growth hormone , recombinant dna , medicine , biopharmaceutical , pharmacology , computational biology , biology , growth hormone , microbiology and biotechnology , immunology , biochemistry , rheumatoid arthritis , gene
Hormone therapies have been used since the early 20th Century and belong to a group of drugs that has recently become known as ‘biologics’. Biologics are medicinal products that have been produced by biological processes as opposed to chemically synthesized drugs. The term biologics spans a wide range of products that include therapeutics such as organs, tissue, cells, blood or blood components, vaccines and proteins. This ‘proteins’ subgroup can be further subdivided into therapeutics such as antibodies, enzymes and hormones. The first hormone therapeutics were extracted from human or animal sources; however, with the advent and development of cloning and protein production technologies from the late-20th Century onwards, protein hormone therapeutics are now produced by recombinant DNA technology.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom